Oslo, Norway, 23 February 2023: Following the announcement on 16 February 2023 of a proposed convertible bond financing of up to NOK 300m with Atlas Special Opportunities ("Atlas"), and the subsequent EGM notice to approve the associated agreements, Targovax’ management invites to a live webcast with a presentation of the main commercial terms and a subsequent Q&A session on Tuesday 28 February at 10am CET.
| Date: | Tuesday 28 February 2023 |
| Time: | 10:00 CET |
| Webcast link: | click here for teams link |
| Presenters: | Erik Digman Wiklund, CEO and Lubor Gaal, CFO |
Please submit any questions in advance to renate.birkeli@targovax.com or directly during the live webcast.
Questions will be accepted in both English and Norwegian and addressed in the respective language.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, multiple myeloma and pancreatic cancer.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. ONCOS-102 has demonstrated a favorable efficacy, immunological and safety profile in several indications, both as monotherapy and in combinations, and ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.
Targovax has also established a cutting-edge circular RNA (circRNA) program with the intent to develop next generation RNA therapeutics for various applications, building on clinical experience and deep mechanistic insights from its first generation products. In addition, Targovax has a KRAS immunotherapy program, with lead candidate TG01 due to enter clinical trials in an enhanced format in pancreatic cancer and multiple myeloma during early 2023. This provides Targovax with a rich pipeline of innovative future therapeutic candidates to follow ONCOS-102.